CBT-501 (genolimzumab) is an immunotherapy that CBT Pharmaceutical is developing to combat solid tumors.
It is called a PD-1 inhibitor because it targets a protein called programmed cell death 1, or PD-1, on the surface of immune cells.
How CBT-501 works
Many cancers have an ability to escape immune system detection.
Immunotherapies are a new type of treatment. They work not by attacking cancer cells directly but by teaching the immune system to recognize and kill the cells.
PD-1 helps shield tumors from the immune system. Blocking it eliminates the shield, allowing the immune system to destroy the cancer.
CBT-501 in clinical trials
CBT Pharmaceuticals’ preclinical-trial studies showed that CBT-501 was as effective as two approved PD-1 inhibitors, Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck’s Keytruda (pembrolizumab), against solid tumors. The study also showed it to be safe and to generate low toxicity.
CBT-501 ‘s clinical trial program is in its early stages.
A Phase 1 trial (NCT03053466), which started in March 2017, continues to recruit people with solid tumors in Australia. Its main objectives are to determine CBT-501’s safety, patients’ ability to tolerate it, and a recommended dose for a Phase 2 trial.
Patients in the Phase 1 trial have advanced-stage solid tumors that have stopped responding to other therapies.
Researchers hope to recruit 50 people for the trial. They can have a variety of cancers, including either colorectal, endometrial, gastric, head and neck, liver, lung, mesothelioma, ovarian, or kidney tumors.
Immuno-Oncology News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.